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INTRODUCTION 
Much of the success in the agricultural field in our country is 
due to the knowledge and use of agricultural insecticides.   Their 
preparations are most popular on one side and on the other side, 
also take many lives every year, though mostly in rural areas but 
also to a considerable extent in the urban areas. 
 In 1976, the World Health Organization (WHO) using data 
from 19 countries estimated that approximately 5,000,000 cases of 
acute pesticide poisoning were occurring annually and resulting in 
9000 or more deaths.  In 1981, the estimate was 7,50,000 cases 
annually while in 1983, the figure was 2 million of which 4000 
were fatal.1 
 It is estimated that in India about 5-6 persons per lakh of 
population die due to poisoning.  The exact incidence of 
organophosphorus poisoning in India is uncertain due to lack of 
data / lack of proper reporting. 
 The commonest types of insecticidal / pesticide poisoning 
are organophosphorus compounds, chlorinated hydrocarbons, 
aluminium phosphide, carbamates and pyrethroids.2 
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 The organophosphorus compounds may be inhaled or 
ingested accidentally or intentionally, in industries, trade, 
agricultural fields or homes. 
 The German chemist Gerhard Schrader is credited for the 
discovery of the general chemical structure of anticholinesterase 
OP compounds,  and for the synthesis of the first commercialized 
OP insecticides.  (Bladan, containing TEPP (Tetra ethyl 
pyrophosphate) as the active ingredient,and for one of the most 
known,parathion in 1944.Since then hundreds of OP compounds 
have been made and commercialized worldwide in a variety of 
formulations10.  
 Organophosphorus compounds are antiacetyl 
cholinesterases which exert their toxicity by interfering with the 
normal function of acetyl choline, an essential neuro transmitter 
throughout the autonomic and central nervous system.   The 
manifestations of toxicity are a result of this effect, affecting the 
patients physiology.  The anticholinesterase effects can be 
evidenced biochemically by suppression in the plasma levels of 
pseudocholinesterase( PChE) and of red cell cholinesterase(AChE). 
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 Previous studies associating the severity or prognosis of 
organophosphorus poisoning with estimation of plasma 
cholinesterase have been contradictory.  GOSWAMY R.et al.,3  in 
their study concluded that apart from clinical indicators, low 
plasma cholinesterase levels were of greatest predictive value for 
respirtory failure in organophosphorus poisoning.  However, 
Aygun D et al.,4 found that plasma cholinesterase level estimations 
are useful in diagnosis of organophosphorus poisoning in acute 
phase, but not with the severity of poisoning. A.Dua et al.,5 studied 
43 patients of organophosphorus poisoning and found that neither 
the mortality nor the clinical severity correlate with plasma 
cholinesterase level. 
Semir Nouira et al., estimated pseudo cholinesterase level at 
the time of admission after organo phosphorus poisoning with the 
aim to determine whether this has got a prognostic value with 
reference to severity, treatment, and need for ventilation. They 
found no correlation between pseudo cholinesterase level and 
organo phosphorus poisoning as per the above assessment.  
 4 
 In view of this, a study was conducted to know the 
usefulness of estimation of plasma cholinesterase in predicting the 
prognosis of organophosphorus poisoning patients. 
In the present study, the group of organophosphorus 
poisoning patients admitted to Tirunelveli Medical College 
Hospital, were assessed clinically as per a standard institutional 
management protocol along with estimation of plasma 
cholinesterase. 
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AIM AND OBJECTIVES  
1. To estimate Pseudo cholinesterase enzyme levels at the time 
of admission in acute organophosphorus poisoning. 
2. To determine whether the Pseudo cholinesterase level has a 
diagnostic significance.  
3. To assess whether the Pseudo cholinesterase levels correlate 
with the severity and outcome of organophosphorus 
poisoning. 
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REVIEW OF LITERATURE 
ANATOMY & PHYSIOLOGY OF NEUROMUSCULAR 
JUNCTION  
ACETYLCHOLINE:  
Acetylcholine (Ach), first synthesized by BAYER in 1867, is a 
neurotransmitter. It was first recognized as a potent 
pharmacological substance by HUNT in 1906.  
Acetylcholine is produced at  
a)Autonomic effector sites innervated by postganglionic                 
   parasympathetic fibres.  
b)Preganglionic autonomic fibres of sympathetic and  
   parasympathetic ganglion cells and adrenal medulla.  
c)Motor end-plates on skeletal muscle  
d)Certain synapses in central nervous system  
The Ach in the motor nerve terminal is synthesized in the 
axoplasm from choline and CoA by a process facilitated by the 
enzyme choline acetyl transferase. The choline necessary for this is 
derived from Extra Cellular Fluid which is transported into the 
nerve terminal by a carrier mediated transport system.
6 
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Choline + Acetyl-Co A   (Choline Acetyl transferase) Acetylcholine  
About 20% of Ach in nerve terminal is present as free Ach in the 
axoplasm, and 80% is contained within the vesicles, each 
containing about  4-5 x 10 
5 
molecules of Ach.  
Separate pools or stores of Ach exist within the nerve 
terminal. Most of the Ach (80%) can be released by nerve impulses 
(the releasable pool), but some cannot (the non-releasable pool or 
stationary pool). The releasable pool consists of the Ach contained 
within the vesicles, whereasnon-releasable pool is the Ach of the 
axoplasm. Releasable pool is often divided into immediately 
available and the reserve pool.  
Acetylcholine acts through two receptors:  
MUSCARINIC RECEPTORS  
Muscarine is a poison from toad stools that activates only 
muscarinic receptors. Effector cells are stimulated by 
postganglionic neurons of the parasympathetic nervous system 
and also postganglionic cholinergic neurons of the sympathetic 
nervous system.  
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NICOTINIC RECEPTORS  
Nicotine will activate the nicotinic receptors in pre and post 
ganglionic neurons of both the sympathetic and parasympathetic 
systems and also in the membranes of skeletal muscle fibres at 
neuromuscular junction.
6 
 
Anatomy of Neuromuscular Junction – The Motor End Plate7 
Metabolism of Acetyl choline:  
Junctional acetyl cholinesterase is the enzyme responsible for 
the hydrolysis of Ach in the synaptic cleft.  
Acetyl cholinesterase is a protein attached to the basement 
membrane of the muscle and probably also to membranes of the 
motor end plates and the nerve terminals. Each molecule of the 
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enzyme is able to bind and hydrolyze several molecules of 
acetylcholine. It has been estimated that for each molecule of Ach 
released by a nerve impulse, there are at least 10 active enzymes 
sites available. This arrangement ensures that each Ach molecule 
only reacts once with the receptor, after which it is rapidly (in < 
1msec) hydrolyzed.7 
TYPES OF CHOLINESTERASE:  
Two major forms of cholinesterase exist in vertebrates which 
hydrolyze acetyl choline 
8,41
 
PLASMA CHOLINESTERASE:(Pseudo or Butyryl Cholinesterase)  
It is found in plasma, liver, pancreas and intestinal mucosa. 
(Liver being the main organ). Variations occur due to liver disease, 
chronic inflammation, malnutrition, morphine, codeine, 
succinylcholine administration and hypersensitivity reactions 
RBC CHOLINESTERASE: ( True, Specific Cholinesterase )  
It is found in nervous tissue, erythrocytes, Lung, spleen and 
grey matter. It is decreased in pernicious anemia and after anti-
malarial therap.y  
Acetylcholine is inactivated by combination with two sites on the 
enzyme RBC cholinesterase: Anionic site and Esteratic site.  
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ANIONIC SITE: Bears a negative charge which attracts the 
quaternary nitrogen ion (N
+
) of acetylcholine. 
ESTERATIC SITE: Attracts the carboxyl group of Acetylcholine 
molecule and the esteratic site of the enzyme is acetylated and this 
results in splitting of choline. The acetyl group in combination 
with the esteratic site is however immediately removed as a result 
of combination with water, forming acetic acid. This sets the 
esteratic site of the enzyme free, for further inactivation of 
acetylcholine.
9 
 
 
It is the esteratic site (shown above) of the 
acetylcholinesterase that the organophosphate compounds bind 
irreversibly to form phosphorylated enzyme. 
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Chemical structure of organophosphorus compounds: 
 Although a number of organophosphorus compounds were 
synthesized in the 1800s, their development as insecticides only 
occurred in the late 1930s and early 1940s.10 Since then, hundreds 
of OP compounds have been made and commercialized world 
wide in a variety of formulations. 
Chemical structure: 
 The chemistry of Organophosphorus compounds has been 
thoroughly investigated.   The general structure of OP insecticides 
can be represented by27  
   R1                 O(or S)       
      
                        
                                         R2                              X 
  
 Where  X is the  so called "leaving group" that is displaced 
when the OP phophorylates acetyl cholinesterase (AchE) and is the 
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most sensitive to hydrolysis.  R1 and R2 are most commonly alkoxy 
groups (i.e OCH3 or OC2H5),though other chemical substitutes are 
also possible; either an oxygen or sulfur are  also attached to the 
phosphorus with a double bond.  Based on chemical differences, 
OPs can be divided into several subclasses, which include 
phosphates, phosphothioates, phosphoramidates, phosphonates, 
and others. 
Pharmacokinetics: 
 The kinetics of OPs are highly dependent on multiple 
physical factors.  Some of these include, route of administration 
(ingestion, injection, inhalation transdermal and transmucosal 
absorption) distant from target organs, local versus systemic 
metabolism and activation, route of elimination, endogenous 
hydrolysis and consumption of the compound by various non 
specific esterases before reaching target organs.  Structural 
considerations include the groups attached to the sulfur, carbon or 
phosphorous moiety, the tightness of bond to the central atom and 
the affinity of the compound for cholinesterase19. 
 Onset of symptoms is fastest with inhaled (within seconds) 
or injected compounds and slowest with transdermal absorption.  
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The majority of agent should show some signs and symptoms of 
toxicity within 6 to 12 hours, but highly fat soluble compounds 
may not manifest toxicity for several days to weeks because the 
substance must be "bleached out" of the fat until sufficient amount 
of cholinesterase is inhibited to cause symptoms.  Compounds that 
require hepatic activation to convert the substance to its active 
toxic state (eg. Parathion to paraxon).   Newer data suggests that 
these residues may remain for days to weeks even after successful 
treatment of initial symptoms20. 
Mechanism of action: 
 Traces of acetylcholine are produced at the myoneural 
junction, which is hydrolyzed to choline and acetic acid 
spontaneously.  Hydrolysis is greatly accelerated by cholinesterase 
which are present in plasma called pseudocholinesterase and on 
the membranes or within cytoplasm of many cells including the 
RBC’s called true cholinesterase.21,22 
 Organophosphorus compounds readily react with and 
inactivate enzymes of cholinesterase type by phosphorylating the 
enzyme at the myoneural junction and synapses of the 
ganglion.The toxic effects of organophosphates are due to the 
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inhibition of acetylcholinesterase, resulting in the excessive 
accumulation of acetylcholine at the synapse. This initially 
stimulates and later paralyzes the cholinergic transmission in the 
CNS,autonomic ganglia,parasympathetic nerve endings,some of 
the sympathetic nerve endings and neuromuscular junctions. 
Mode of action: 
 Cholinesterase has special reactive sites on its surface, the 
esteratic site and the anionic site19.  Acetylcholine is hydrolysed in 
the following manner. 
 Electrostatic bond is formed between the quaternary 
nitrogen on choline and anionic site on the enzyme.   This is 
further strengthened by auxillary bonds between two of the 
methyl groups on the nitrogen and the surface of the enzyme.  
Finally a covalent bond is formed between the carbonyl atom of 
acetate and the esteratic site.  Acetylation is rapidly followed by 
breakage of the ester linkage and the elimination of the choline.  
Acetylated enzyme then reacts with water to regenerate the 
enzyme and release acetic acid. 
 Most of these compounds do not possess a positive charge, 
hence they react with esteratic site, but not with the anionic site.  
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Splittering of the acid group then occurs.  However the bond 
between the phosphorus and esteratic site is more stable than the 
bond between the carbon atom of acetyl choline and the same site.  
This results in the blocking of the active site and consequent 
inactivation of enzymes.  This results in accumulation of acetyl 
choline at cholinergic sites and consequent clinical effects.  Pseudo 
cholinesterase is a less specialized enzyme as it lacks an anionic 
site in a position that specially adapts it to react with acetylcholine.  
It does, however react with acetylcholine more slowly and also 
with a wide range of other esters. 
Clinical presentation of acute toxicity: 
 Signs and symptoms of cholinesterase inhibitor poisoning 
are related to their effects on three separate areas of cholinergic 
nervous system19,42. 
1. Post ganglionic parasympathetic hollow end organ 
(muscarinic) effects. 
2. Sympathetic and parasympathetic ganglionic and somatic 
neuromuscular junction (nicotinic) effects. 
3. Central nervous system effects. 
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Muscarinic symptoms noted are as follows; 
 Tearing, 
 Drooling of saliva, 
 Profuse Diaphoresis, 
 Emesis, 
 Urinary and fecal incontinence, 
 Gastro intestinal cramping,  
 Bronchospasm and Bronchorrhoea, 
 Miosis, Bradycardia, Hypotension, 
 Conduction blocks. 
Nicotinic symptoms include; 
 Respiratory difficulty, 
 Respiratory arrest, 
 Diaphragmatic weakness, 
 Muscle weakness, fasciculations, 
 Clonus, tremor, mydriasis, hypertension, 
 Tachycardia, 
 Re entrant dysrhythmia, cardio respiratory arrest, 
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CNS symptoms include; 
 Malaise, memory loss, confusion, disorientation, delirium, 
seizures, coma. 
Intermediate syndrome (IMS) 
 First termed as type II paralysis and subsequently as 
Intermediate Syndrome(IMS).It occurs 24 to 96 hours after 
resolution of acute cholinergic crises26,34.  Clinical features include 
respiratory failure, bulbar, nuchal and proximal limb muscle 
weakness.  Electromyographic studies show decremental 
conduction with repetitive nerve stimuli.  Recovery is associated 
with incremental conduction and normalization of 
Electromyograms.   The intermediate and delayed symptoms do 
not respond to atropine or other drugs36. 
Organophosphate induced delayed neurotoxicity (OPIDN) or 
polyneuropathy (OPIDP) 
 It is a sensori motor polyneuropathy that occurs 1 to 3 weeks 
after exposure to certain organophosphates (disopropyl fluro 
phosphate, leptophos, diazinon, merphos).  The initial toxicity may 
be mild without the full blown cholinergic presentation.  The 
patient initially complains of distal motor weakness in the lower 
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extremities and sensory paresthesias.  Eventually the patient 
develops calf cramping and pain.  The motor weakness progress to 
muscle atrophy and paralysis with foot drop.  Ataxia develops and 
the distal tendon reflexes are lost.  The neuropathy continues to 
spread involving upper extremities and eventually develop into a 
flaccid symmetric paralysis that mimics Guillian Barre syndrome.  
Some patients may recover over 12 to 15 months, but permanent 
losses with spasticity and persistent upper motor neuron finding 
have been reported.19, 24, 35. 
 On a pathological level, the large distal neurons develop 
axonal degeneration followed by myelin degeneration.   This has 
been called the "Dying back" phenomenon.  Degeneration occurs 
in association with the onset of paralysis and ataxia. 
The identified target esterase for OPIDP present in nervous 
tissues as well as other tissues was named as Neuropathy Target 
Esterase(NTE)43. 
Chronic toxicity: 
 Patients with chronic low level exposure may not show any 
signs and symptoms until cholinesterase has been inhibited 
beyond a critical point.  The body can maintain normal physiologic  
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function until cholinesterase activity is inhibited by 20 to 50 
percent.19 
 Impairment of pseudo cholinesterase function during 
chronic exposure to cholinesterase inhibitors also affects levels of 
medications and toxins that are normally metabolized by pseudo 
cholinesterase.   These include succinylcholine, morphine, codeine, 
esmolol and local ester anesthetics such as cocaine and tetracaine. 
Psychological effects: 
 Psychological difficulties (Hallucinations, delusions, 
irritability, nervousness, anxiety, memory loss, depression, 
dissociation, schizophrenic reactions, behavioral or mood changes) 
have been reported in a large number of earlier studies related to 
occupational exposure to agricultural insecticides.21,24 
Paediatric considerations: 
 Infants and neonates have lower baseline cholinesterase 
activity and are at increased risk when exposed to equal amount of 
organophosphorus compounds.  Their under developed, less 
myelinated nervous system may show additional long term 
toxicity. Cholinesterase levels are also depressed during 
pregnancy, especially during the first two trimesters.19, 25. 
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THE ROLE OF ESTIMATION OF PSEUDO CHOLINESTERASE 
 Estimation of acetyl cholinesterase level in circulation is 
theoretically preferred in organophosphorus poisoning since it 
would reflect the degree of inhibition of synaptic cholinesterase at 
motor end plates. But in practice estimation of plasma 
cholinesterase has advantage because the    measurement is simple 
and more accurate than estimation of acetyl cholinesterase.  
Pseudo cholinesterase levels can indicate the prior presence of 
cholinesterase inhibition even after recovery of acetyl 
cholinesterase activity by pralidoxime in organophosphorus 
poisoning.11 
The normal values range between 5100 to 11700 U/L. 
According to Proudfoot,12 the Organophosphorus poisoning may 
be classified based on the levels of Pseudo cholinesterase (PChE) 
on presentation as follows :  
 In mild poisoning: PChE level is 20 - 50 % of normal  
 In moderate poisoning: : PChE  level is 10 - 20 % of normal  
 In severe poisoning: : PChE  level is < 10 % of normal  
 21 
The confirmation of diagnosis depends on demonstrating reduced 
cholinesterase activity in the circulating blood.  
 
CHANGES IN ACETYLCHOLINESTERASE LEVELS DURING 
POISONING AND TREATMENT  
 Plasma cholinesterase inhibition depends on the 
concentration of the inhibitor, as this is subject to continuous 
unknown fluctuations and it is not possible to predict the 
time course of inhibition. Enzyme inhibition will proceed 
until a steady state is reached and spontaneous reactivation 
is achieved.  
 Cholinesterase activity of red blood cells is instantly and 
completely restored and long lasting, but the return of 
activity of pseudo cholinesterase (PChE) is transient and 
variable after oximes. (The main effect produced by the 
administration of oximes is the restoration of the true 
acetylcholinesterase activity & prompt and complete relief of 
symptoms, especially after alkylphosphate poisoning. True 
cholinesterase level indicates effectiveness and pseudo 
cholinesterase levels indicate the prior presence of 
cholinesterase inhibition. 11 
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Diseases as a source of variation on the pseudo cholinesterase 
activity:  
Normal levels are seen in uncomplicated obstructive 
jaundice, myasthenia gravis, hyperthyroidism, asthma, 
hypertension, epilepsy and diabetes mellitus.  
Low levels are observed in patients with parenchymal liver 
disease, thiamine malnutrition, etc., In patients with liver disease 
not only do they have decreased levels but a further decrease 
ensues as a result of exposure to an organophosphorus compound. 
Plasma cholinesterase is sharply reduced in acute myocardial 
infarction and below normal in dermatomyositis. Nephrotic 
syndrome patients have increased levels of pseudo 
cholinesterase.32  
Disadvantages of pseudocholinesterase estimation:  
1. Normal values of pseudo cholinesterase are widely variable 
from one person to another as well as in the same individual at 
different times.  
2. Low pseudo cholinesterase levels have been observed in some 
disease states and may also be genetically determined.  
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3. Following pralidoxime administration, true cholinesterase levels 
indicate the effectiveness of PAM and pseudo cholinesterase 
levels indicates prior presence of cholinesterase inhibition even 
after recovery of true cholinesterase activity by PAM, hence the 
latter cannot be used to assess the effectiveness of PAM 
therapy.  
4. Pseudocholinesterase level at a particular time in the blood is 
not constant but continuously changing as the inhibition of the 
enzyme by inhibitors and spontaneous reactivation will take 
place simultaneously.  
5.  Different OP compounds may inhibit trueChE or PChE to a   
     different degree.For example the oxygen analogs of   
     malathion,diazinon and chlorpyriphos are stronger inhibitors of   
     PChE than RBC AChE.29 
Management Of Acute Organophosphorus Poisoning:
 8,13
 
1. Supportive measures:   
Oral suction of secretions  
Maintenance of circulation  
Establishment of respiration 
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2. Prevention of absorption:  
Decontamination  
Emesis  
Adsorbant  
Cathartics  
Bowel wash  
3. Specific chemotherapy:  
Atropine  
Oximes  
4.Treatment of complications 
1. Supportive measures:  
It should be ensured that upper airway is not blocked and 
throat secretions should be intermittently sucked to avoid 
aspiration. Respiratory insufficiency is the commonest cause of 
death. Hence, positive pressure ventilation should be given if 
patient develops signs of respiratory failure.  
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2. Prevention of absorption:  
a. Decontamination:  
Contaminated clothing should be changed, skin should be 
washed.  
b. Emesis:  
Unless the patient is comatosed, convulsing or has lost the 
gag reflex emesis should be initiated. Should these 
contraindications be present, endotracheal intubation should 
precede gastric lavage with wide bore tube.  
c. Adsorbant:  
Activated charcoal functions as an adsorbant and should be 
given within 3 hours of ingestion and if gastric emptying is 
delayed it may be useful for upto 12 hours after ingestion. It is the 
most valuable single agent for emergency management of oral 
drug poisoning.  
d. Cathartics:  
Cathartics function by decreasing absorption and increasing 
elimination. It should be administered as early as possible because 
relapse is thought to be due to delayed absorption.  
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e. Bowel wash :  
To be done twice a day which helps to remove toxic 
substance from large bowel.  
3. Specific therapy: 1,11 
1. Atropine: It is an alkaloid derived from a plant Atropa 
belladona and Datura stramonium. Atropine acts as a 
physiological antidote, effectively antagonising the muscarinic 
receptor- mediated actions of organophosphorus agents. Dose of 
atropine should be sufficient to produce signs of atropinisation.  
Pharmacological action:  
At autonomic ganglia where transmission mainly involves 
nicotinic receptors, atropine produces partial blockade at high 
doses. Atropine does not inhibit the nicotinic actions of 
acetylcholine. To some extent it inhibits the central effects 
produced by these compounds. Thus, atropine antagonises mainly 
the muscarinic effects of organophosphorus poisoning. Atropine is 
partially detoxified in the liver and partly excreted unchanged in 
the kidney.  
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Dosage:  
In order to prevent pulmonary edema, early prompt 
atropinisation is important. Severe poisoning may require heavy 
doses, upto 100 mg over first 24 hours to achieve adequate 
atropinisation.  The best clinical approach is, to administer doses 
of atropine large enough to achieve evidence of atropinisation. 
Atropinisation should be maintained for at least 48 hours.28  Higher 
doses by continuous infusion may be required in severe cases. 
Overdosage with atropine is rarely serious in OP poisoned 
patients.28 
Signs of atropinisation:  
Pupillary dilatation cannot be taken as an indication of 
atropinisation since organophosphorus compounds can produce 
both miosis or mydriasis. Pupils becoming initially pin point later 
becoming dilated is a reliable sign of atropinisation. Since 
tachycardia and bradycardia can occur, tachycardia (130 – 
140/min.) cannot be a reliable sign. Other signs include flushing, 
dry skin and dry mouth. Full atropinisation is indicated by 
clearing of rales and drying of pulmonary secretions.14, 26 
 28 
 
Adverse Effects:  
Dry mouth, hot dry skin, thirst, flushing, fixed dilated pupil, 
tachycardia, impaired speech, tremor, coma, convulsions, 
respiratory failure and collapse.31, 33.  
2. Oximes:  
DOSAGE: Pralidoxime - 1 gm IV followed after 15-30 minutes,by 
another 1gm if no improvement seen. If no improvement,infusion 
of 500 mg/ 
 
hr can be started.28 
Obidoxime - 3-6 mg / kg IV over 5-10min.  
D.A.M. (Diacetyl Monoxime) -1-2 gm IV slowly at 200 mg / min to 
be repeated after 20 min. 
 While animal data consistently show a marked positive 
effects of oximes some authors reported limited or no efficacy of 
oximes in the treatment of OP poisoning.40  Organo phosphates 
containing two methoxy groups (malathion, methyl parathion, 
dimethoate) is considered to be rather resistant to oxime therapy.38  
Inadequate dosing has been held as a major factor for lack of 
response to oxime therapy.39 
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 A recent meta-analysis of several studies of OP poisoned 
patients concluded that use of oximes was associated "with either a 
null effect or possible hasm".37  
The IV administration of PAM usually produces slight to 
moderate reversal of plasma and red cell cholinesterase inhibition but has 
no effect on the gastrointestinal symptoms, tachycardia, sweating, 
salivation or on CNS symptoms produced by anticholinesterase 
compounds. 
Enzyme reactivation occurs most markedly at the 
neuromuscular junction with rapid improvement of skeletal 
muscle response. An important effect of this action is 
normalisation of diaphragmatic excursion and respiratory effort. 
To be effective, oximes should be given within 36 hours of 
poisoning, after which it becomes ineffective by a process called 
'ageing'. Phosphorylated cholinesterase undergoes ageing and the 
aged enzyme is resistant to oxime action and cannot be 
reactivated.1,13 
Oximes are effective in severe cases of poisoning presenting 
with pulmonary edema, muscular twitching, muscle weakness and 
respiratory paralysis. Prompt recovery of consciousness by many 
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patients indicate that it has a definitive CNS effect in 10- 15 min. In 
clinical practice, even 2 or 3 days after onset of poisoning, Oximes 
might be useful probably because newly inhibited cholinesterase is 
constantly produced as a result of the continuing absorption of 
organophosphorus compounds from the GIT or other tissue.  
Pralidoxime is preferable since it is more soluble and produces 
fewer side effects. When given in large doses at the proper time, 
PAM antagonises the CNS effect of organophosphorus 
compounds.
 
 
Adverse effects:  
In higher doses, oximes can inhibit cholinesterase enzyme 
and they can cause neuromuscular blockade. If infused rapidly 
they can cause weakness, drowsiness, giddiness, blurred vision, 
diplopia, headache, nausea, tachycardia and 
hypotension.Obidoxime can lead to hepatic failure.26 
3.Treatment Of Complications :  
Seizures, Pulmonary edema, Pneumonia, Adult respiratory 
distress syndrome (ARDS), Renal failure, Hypotension / shock, 
arrhythmias, etc. are all managed as per standard protocol.1 
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MATERIALS AND METHODS 
  100 patients with history and clinical features of 
organophosphorus poisoning admitted to the IMCU of Tirunelveli 
Medical College hospital between October 2009 to August 2010 
were included in this study.   Patients were selected irrespective of 
their age or sex. 
INCLUSION CRITERIA for the study were as follows: 
1. Provisional diagnosis of organophosphorus poisoning in a  
patient irrespective of age / sex, based on history by 
attenders.  This was substantiated by examination of the 
containers.  
2. Clinical features suggestive of severe grade of 
organophosphorus poisoning with clinical evidence of 
respiratory insufficiency. 
EXCLUSION CRITERIA for the study as follows: 
1. Patient with double insecticide / multiple poisoning with 
other drugs such as opioids, diazepam, barbiturate etc. 
2. Patients with history of respiratory diseases like bronchial 
asthma, cardiac diseases, neuromuscular diseases like 
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myasthenia graves or muscular dystrophy or other 
concomitant illness. 
Each patient enrolled for study underwent a detailed clinical 
examination as per a proforma, specifically designed for the 
study. All patients were monitored  closely and continuously 
in the IMCU  and all clinical signs assessed ½ hourly till  
complete recovery.  Ventilator support was considered in 
patients with features of respiratory failure as evidenced by, 
• Apnoea or obvious hypoventilation 
• Persistent cyanosis. 
• Persistent Tachypnoea (RR>24/min)  
• Persistent SP O2 < 90% with oxygen supplementation by non 
invasive means. 
• Active involvement of accessory muscles of respiration. 
• All patients underwent baseline biochemical investigations. 
• Pseudo cholinesterase levels were estimated at the time of 
admission. 
The blood samples for pseudo cholinesterase estimation 
were taken along with Anticoagulant heparin or EDTA. 
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(The kit used in this study for the estimation of pseudo 
cholinesterase was AGAPPE diagnostics cholinesterase reagent 
kit) 
 The pseudo cholinesterase activity was measured by 
kinetic/DGKC calorimetric method of AGAPPE diagnostics. 
 The results are expressed in U/L.  The laboratory reference 
range used in the present study for pseudo cholinesterase  is 4620-
11500U/L 
 Based on the pseudo cholinesterase values, the severity of 
poisoning may be defined as per (Proud foot classification)12 ,with 
above normal range. 
• Mild  poisoning PChE level 20 - 50%  of normal / 
>2001 U / L 
• Moderate poisoning PChE level 10 – 20% of normal / 
(1001 – 2000 U/L) 
• Severe poisoning : PChE level is <10% of normal / 
<1000 U/L. 
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OBSERVATION AND RESULTS 
 
 In this present study, the study subjects were analysed 
according to their demographic characteristics by computing the 
averages and compared by the test of significance students 't' tests.  
The study variables and attributes were correlated and associated 
by correlation coefficients and χ2 (Chi-square) tests where ever 
applicable.  The above statistical procedure were undertaken by 
statistical package S.P.S.S (13.0).   The  value of P <0.05 was treated 
as significant. 
AGE-SEX DISTRIBUTION: 
 The study subjects were compared according to their age 
and sex. 
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Table-1  Age and sex wise distribution of clinical trials. 
Male Patients Female Patients Total Patients  Age  
group (years) No. % No. % No. % 
13-19 8 12.3 5 14.3 13 13.0 
20-29 31 47.7 10 28.6 41 41.0 
30-39 13 20.0 15 42.8 28 28.0 
40-49 7 10.8 3 8.6 10 10.0 
50-59 4 6.2 2 5.7 6 6.0 
60-69 2 3.0 0 0.0 2 2.0 
Total 65 100.0 35 100.0 100.0 100.0 
Mean ±S.D 30.4 ±11.3 31.4±10.1 30.7±10.8  
't' 0.438 -  
Significance d.f = 98 and P>0.05 -  
  
The study subjects were described according to their 
demographic characteristics such as age and sex in the above  
table-1.  The male and female proportions were 65% and 35% 
respectively.  The median age with range of age was 27 (16-64) for 
males.  The females median age was 31(17-59) years.  The total 
subjects median age was 29 (16-64) years.  The mean age of males 
and females were 30.4 ±11.3 and 31.4±10.1 years respectively.  The 
mean ages between the sexes was not statistically significant 
(P>0.05).  The mean age of total subjects was 30.7 ± 10.8 years. 
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TABLE-2  Range of Pseudocholinesterase levels among patients 
Range of PChE in 
U/L 
Severity No of cases Percentage 
<1000 
1001 – 2000 
2001 – 3000 
3001 – 4000 
4001 – 5000 
>5000 
Severe 
Moderate 
Mild 
Mild 
Mild 
Normal 
6 
17 
45 
21 
2 
9 
6% 
17% 
45% 
21% 
2% 
9% 
Mean - PChE                                             2726.04 ± 1205.377 U / L 
Reference value in this study is 4620 – 11500 U / L 
 
The above table shows the PChE levels of 100 patients at the time 
of admission. The mean level in this study was found to be  
2726.04 ± 1205.377  U / L in  reference to a normal value of 4620 – 
11500 U /L.   About 89% of patients had a level PChE < 4000  U /L. 
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Table-3.  PChE level among the recovered and expired patients 
PChE level in 
U/L 
Outcome  No. of 
patients 
Mean S.D 
Difference 't' 
value 
d.f Significance 
Recovered 76 2781.5 1281.1 
Expired 24 2550.5 927.4 
Total 100 2726.0 1205.4 
 
231.0 
 
0.817 
 
98 
 
P > 0.05 
 
The PChE level of recovered patients and expired patients were 
compared in the above table. Of the total 100 patients studied 76 
recovered whereas 24 expired. Recovered group had a mean PChE 
level of 2781.5 + 1281.1 U/L. expired group had a mean PChE level 
of 2550.5 + 927.4. U/L the difference between them was not 
statistically significant. 
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Comparision of time delay (consumption to admission) with 
PChE level. 
 The time interval taken to admit the patients to the hospital 
after consumption of poison, was calculated and the same was 
compared with level of  PChE as follows. 
Table -4 Comparison of duration of time with PChE level.   
PChE level in U/L Duration of      
Time(hours) < 1000 
(Severe) 
1000-2000 
(moderate) 
 
2000 and       
above (mild)   
Total 
No. of 
patients 
χ2 d.f Signi 
ficance 
0-2 0 0 2 2 
2-4 2  7 15 24 
4-6 2  4  35 41 
6-10 1  5 21 27 
> 10 1  2 3 6 
Total 6 18 76  100 
 
 
 
7.902 
 
 
 
8 
 
 
 
P>0.05 
  
 The PChE level of the patients compared with the time delay 
was presented in the above table-4. Among the 100 patients, 6 
showed severe suppression (<1000 U/L), 18 patients showed 
moderate suppression (1000-2000) and the remaining showed mild 
suppression (2000 and above) of PChE according to Proud foot 
classification.    
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Among the 6 patients with severe depression of PChE , 2 
patients were admitted within 2 - 4 hours, 2patients within 4 – 6 
hours, 1 patient within 6 – 10 hours and 1 patient >10 hours after 
poisoning. The duration of time was not associated with the level 
of PChE.    (P>0.05).  
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Biochemical profile: 
 The biochemical  statistics such as blood glucose level, urea 
and creatinine were analysed and the results are as follows. 
Table-5 Biochemical profile of the study subjects. 
Blood glucose Urea Creatinine 
Level (mg/dl) No of person 
(frequency) 
Level 
(mg/dl) 
No of 
persons 
Level 
(mg/dl) 
No of 
persons 
50-100 23 15-20 1 0.5 - 0.75 1 
100-150 63 20-25 56 0.75 – 1.00 30 
150-200 13 25-30 26 1.00 – 1.25 65 
200 and  above 1 30 and 
above 
17 1.25 - 1.5 4 
Total  100 Total 100 Total 100 
Mean ±S.D 121.1±31.6  25.3±6.4 1.0±0.14 
 
 The related biochemical values were described in the above 
table-5.  The mean blood glucose level was 121.1 ± 31.6 mg/dl.  
The same of the other two variables namely urea and creatinine 
were 25.3 ±6.4 and 1.0±0.14 mgm/dl.respectively. 
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Comparision of PChE  level and outcome with route of exposure 
Table-6 Comparision of route of exposure with PChE  level. 
PChE level  U/L Route of 
exposure 
 
 Severe  
<1000 
  
Moderate                
1000 - 2000 
Mild 
 >2000  
Total No. of 
patients 
χ2 d.f Significance 
Inhalation 1 2 9 12 
Oral 5 16 67 88 
Total 6 18 76 100 
 
0.139 
 
2 
 
P>0.05 
  
 The route of exposure was associated with the PChE level in 
the above table-6.  The results of the test of significance revealed 
that there was no association between the route of exposure and 
the PChE level (P>0.05). 
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Table-7 Relation between route of exposure and outcome. 
Route of 
exposure 
Expired 
No. of 
patients 
Recovered 
No. of 
patients 
Total  
 No. of 
patients 
χ2 d.f Significance 
Inhalation 4 8 12 
Oral 20 68 88 
Total 24 76 100 
 
0.651 
 
1 
 
P>0.05 
 
 The above table-7 explains the relationship between the 
route of exposure and the outcome of patients.  The chi-square 
value (0.651) at 1 degree of freedom reveals that there was no 
statistically significant association between the route of exposure 
and out come (P>0.05) 
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PChE  level and outcome related with symptoms. 
 The PChE level and outcome of the patients were related 
with symptoms of patients. 
Table -8 Symptoms related with PChE  level. 
 PChE level U/L Symptoms 
Severe  
< 1000 
  
Moderate 
1000 - 2000 
 
Mild    
> 2000 
  
Total 
 No. of 
patients 
χ2            d.f     Significance 
M 4 12 36 52 
M + N 2 5 33 40 
M + N + C 0 1 5 6 
N + C 0 0 2 2 
Total 6 18 76 100 
 
 
3.308 
 
 
6 
 
 
P>0.05 
   
M- muscarinic ;  N- nicotinic ; C- central nervous system features 
The above table-8 describes the relation between the 
symptoms and  PChE level.  The Muscarinic (M) symptoms were 
found in 52% of patients.  The remaining symptoms M+N, 
M+N+C and N+C were found in 40%, 6% and 2% respectively.  
The symptoms were not related with PChE level since  there was 
no statistically significant association  between them (P>0.05). 
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Table -9  Symptoms related with outcome. 
Expired Recovered Symptoms 
No % N o % 
Total  χ2 d.f Significance 
M 1 4.2 51 67.1 52 
M+N 17 70.8 23 30.3 40 
M+N+C 4 16.7 2 2.6 6 
N+C 2 8.3 0 0.0 2 
Total 24 100 76 100 100 
 
 
33.722 
 
 
3 
 
 
P<0.001 
 
M- muscarinic ;  N- nicotinic ; C- central nervous system features 
 The above table-9 associates the symptoms and outcome of 
the patients. The muscarinic symptoms were statistically 
significantly associated with recovered  patients, since 67.1% of the 
recovered patients had only muscarinic symptoms.  The symptoms 
M+N, M+N+C and N+C were statistically associated with expired 
patients.  There was statistically a very highly significant  
association between the symptoms and outcome (P<0.001). 
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Respiratory Failure compared with PChE level and outcome 
 The poisoned patients were compared according to the 
presence of respiratory failure with PChE level and outcome. 
Table -10 Association of respiratory failure  with PChE level. 
PChE level U/L Respiratory 
failure Severe     
<1000 
Moderate 
1000 - 2000 
Mild  
>2000  
 
No.of 
patients 
χ2 d.f Significance 
Yes 2 11 34 47 
No 4 7 42 53 
Total 6 18 76 100 
 
2.045 
 
2 
 
P>0.05 
 
The above table-10 illustrates that the respiratory failure 
cases were 47%and non respiratory failure cases were 53%.  The 
respiratory failure was not statistically significant with PChE level 
(P>0.05)  
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Table -11 Relationship between respiratory failure with the  
outcome of patients. 
Respiratory 
failure 
Expired 
No. of 
patients 
Recovered 
No. of 
patients 
Total 
No. of 
patients 
   χ2    
 
 
d.f 
 
 
Significance 
 
 
Yes 23 24 47 
No 1 52 53 
Total 24 76 100 
 
0.5498 
 
100 
 
P<0.001 
 
 The respiratory failure cases were correlated with outcome 
of patients in the above table-11.  Among the expired group the 
respiratory failure presented in 95.8%(23 out of 24).  Only one  
(4.2%) patient expired among the non respiratory failure cases.  
The correlation was statistically very highly significant (P<0.001). 
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Atropine Requirement with PChE level and outcome 
 The quantity of atropine administered was associated with 
PChE level and outcome of the patients. 
Table -12 Association between atropine requirement with PChE 
level. 
               PChE level U/L Level of 
atropine used 
in mgm 
Severe 
<1000 
Moderate 
1000-2000 
Mild 
>2000 
Total No. 
of 
patients 
 
Χ2 d.f Significance 
<100 0 1 5 6 
100-200 2 5 42 49 
200-300 3 8 22 33 
300-400 1 4 7 12 
Total 6 18 76 100 
 
6.759 
 
6 
 
P>0.05 
 
 
 The above table 12 states that the atropine requirements of 
the patients were not statistically correlated with the PChE level.  
(P>0.05) 
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Table –13 Correlation between Atropine requirement and  
outcome.  
Expired Recovered Total Atropine  
Dosage in 
mgm 
N o % N o % N o % 
<100 0 0.0 6 7.9 6 6.0 
100-200 9 37.5 40 52.6 49 49.0 
200-300 10 41.7 23 30.3 33 33.0 
300-400 5 20.8 7 9.2 12 12.0 
Total 24 100 76 100 100 100 
Mean ±S.D 231.0 ± 78.0 191.3 ± 77.8 200.8 ± 79.3 
't' 2.170  - 
Significance d.f = 9 and p<0.05 - 
 
 The atropine administered to the poisoned patients was 
correlated with the outcome. The mean atropine administered to 
the expired patients was 231.0 ± 78 mgm and the same 
administered to the recovered patient was 191.3 ± 77.8 mgm.  The 
difference of mean 39.7 was statistically significant (P<0.05).  The 
relationship between the atropine and outcome was statistically 
significant (P<0.05). 
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DISCUSSION 
Age sex distribution   
           In our study it was found that majority of the patients were 
males (65%). This could be because males have easy accessibility to 
organophosphorus compounds . Majority of patients (69%) 
belonged to the age group of 20 -39 years( Mean age – 30.7 ± 
10.8years). 
     Major route of poisoning was by oral ingestion. There was 
no correlation between route of poisoning and outcome or PChE 
level. 
      Nearly 74% of patients were brought after 4hours of 
poisoning. 
This could be related to the fact that majority of patients 
were from rural areas and needed to be brought to the hospital for 
management by road. 
The  mean blood glucose level was 121.1 ± 31.6 mg/dl.  The 
same of the other two variables namely urea and creatinine were 
25.3 ±6.4 and 1.0±0.14 mgm/dl respectively. 
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PSEUDOCHOLINESTERASE LEVEL AT THE TIME OF 
ADMISSION. 
In our study, taking into consideration the lower limit of 
reference value of PChE, only 9 patients had PChE value of more 
than 4600 indicating that there was suppression in more than 90% 
patients on admission.(reference range 4620 – 11500 U/L). 
 The mean PChE level was 2726.04 ± 1205.377 U/L 
A. Dua et.al.,5 also found that  PChE was lower than normal 
in all their study patients with OP poisoning . 
Suvit areekul et. al., 15  studied 10 patients with OP poisoning 
and found reduced level of PChE in all of them with one mortality. 
In 23  cases of OP poisoning Mehta A.B et al., 16  observed  
lower activity of PChE in more than 70% of cases at presentation. 
       Thus reduced level of PChE  at the time of admission can 
raise a strong suspicion of OP poisoning . 
 RELATIONSHIP BETWEEN MORTALITY AND PChE 
There was a mortality rate of 24% in our study with no 
relation to PChE level. 
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The mean PChE level of expired group was 2550.5 + 
927.4U/L. 
The mean PChE level of recovered group was 2781.5 + 
1281.1U/L. 
The difference between the two was not statistically 
significant. 
          Mehta.A.B.  et al.,16 reported similar patterns in their study 
wherein 2 patients with severe suppression ( values of < 10%  
PChE )could survive.  
           J.Sunder ram  et al.,17 observed a mortality of 8% ( 4 out of 
45) with no correlation with PChE values. 
           A. Dua et al.,5   studied 43 patients of OP poisoning and 
found that neither the mortality nor the clinical severity correlate 
with PChE level. This indicates that there is no relation between 
mortality and PChE levels. 
TIME DELAY  FROM POISONING TO ADMISSION 
Only 6 patients were admitted after 10 hrs. Among them 
only 1patient  had severe and 5 patients had mild to moderate 
suppression,Similarly among the patients showing severe 
suppression of PChE levels (6%), only one patient was admitted 
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after 10hrs, 33% of patients were admitted within 4 hrs.Thus there 
was no relation between the time delay from poisoning to 
admission and PChE level suppression.This can be explained as 
the amount of toxin taken is more important than the time delay.  
RELATION OF SYMPTOMS WITH PChE LEVELS  
Majority  of patients( 98%) presented with muscarinic 
features. Of these 52%  presented with only muscarinic features 
and they constitute 67 % of recovered group. 
      The patients with associated  nicotinic features were 48% and 
they  constitutes 96% of expired group.  
    Thus presence of nicotinic features indicate more chances of 
mortality. 
   Among the patients with only muscarinic features (52), 
severe suppression of PChE levels was seen in 4; moderate 
suppression in 12; and mild suppression in 36 patients. Among the 
patients with associated nicotinic features (48), severe suppression 
in 2; moderate suppression in 6; and mild in 40 patients. Thus 
there was no correlation between symptoms and PChE levels. 
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RELATION OF PChE LEVEL WITH RESPIRATORY FAILURE 
Respiratory failure cases were 47 in this study. Among them 
majority (34 out of 47 ) had only mild PChE level suppression. 
Among the patients having severe suppression(6), the non 
respiratory failure cases were 4.Thus there was no significant 
correlation between PChE level and the presence of respiratory 
failure. 
RELATION OF RESPIRATORY FAILURE AND OUTCOME  
Among the expired group of patients, presented with 
respiratory failure was 95.8% . The relationship between 
respiratory failure and mortality was highly significant. 
Thomas Chang-Yao Tsao et al., 30 found over a five year 
period that respiratory failure developed in about 40% of organo 
phosphorus poisoning or carbamate poisoning and half of them 
died due to respiratory failure. 
         Semir nouira et al., 14 did not find any statistically significant 
difference in mean PChE levels in those mechanically ventilated 
and those not needing ventilator support. 
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     Wadia et al., 18 found no correlation between various clinical 
signs and levels of RBC Cholinesterase and PChE. 
    Mehta et al.,16 also found no correlation between severity of 
poisoning clinically and PChE levls in their study. 
Most of the above studies indicate that there is no correlation 
between PChE levels and the clinical severity of poisoning, such as 
presence of respiratory insufficiency. Also PChE levels do not 
appear to have any prognostic value as far as OP poisoning is 
concerned. 
RELATIONSHIP BETWEEN PChE AND TOTAL DOSE OF 
ATROPINE REQUIRED 
The average dose of atropine required was 250.8 ±79.3mg. 
Among the 12 patients administered higher doses of atropine (300 
– 400mg) , 7 patients showed only mild suppression of PChE level. 
Thus there was no clear correlation between atropine dosage 
administered and PChE levels in our study. 
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RELATIONSHIP BETWEEN OUTCOME AND TOTAL DOSE 
OF ATROPINE REQUIRED 
     The mean atropine required in expired patients were 
significantly higher than that required in recovered patients.Thus 
higher requirement of atropine in a patient can be taken as a 
predictor of severity and mortality. 
  Semir nauira et al., did not find any statistically significant 
differences in mean PChE levels in those mechanically ventilated 
and those not needing ventilator support. They found that the total 
dose of atropine required and the simplified acute physiology 
score ( SAPS) used to grade clinical severity, did not correlate with 
the  PChE values. 
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CONCLUSION 
The present study on pseudo cholinesterase levels in 
organophosphorous poisoning patients was conducted in 100 
patients admitted in Intensive Medical Care Unit of Tirunelveli 
Medical College Hospital.                                                                                                                                                   
1.We found in our study that the patients were predominantly   
   males, between the age group of 20 to 40 years. There was   
   significant association between the presence of nicotinic features  
   or respiratory failure, atropine dose used and outcome of   
   poisoning. 
2.In majority of cases, we found suppression of Pseudo  
   cholinesterase level at the time of admission to the hospital,  
   which confirms the diagnosis of organophosphorus poisoning.   
However our study did not reveal any relation between  
• PChE levels and the time of presentation after poisoning 
• PChE levels and respiratory insufficiency 
• PChE levels and atropine dose used 
• PChE levels and mortality 
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                                                           PROFORMA 
1.Name of the patient   : 
2.Age                            : 
3.Sex                             : 
4.In Patient Number   : 
5.Time of exposure of OPC  : 
6.Route of exposure   : 
7.History of present illness  : 
     a.Tightness in the chest  : 
     b.Nausea,Vomiting   : 
     c.abdominal cramps   : 
     d.Diarrhoea    : 
     e.Involuntary defecation  : 
     f.Excessive sweating  : 
     g.Exessive salivation  : 
     h.exessive lacrimation  : 
     i.blurring or dimness of vision : 
     j.involuntary micturition  : 
     k.muscle twitching   : 
 64 
     l.respiratory difficulty  : 
     m.irritability    : 
     n.loss of consciousness  : 
     o.convulsions    : 
G/E 
     Pulse  : 
     BP   : 
     RR  : 
     Temp  : 
SYSTEMIC EXAMINATION 
CNS 
      GCS  : 
                                                        Rt                                    Lt 
      PUPIL SIZE : 
      SPINO MOTORSYSTEM  : 
      Deep Tendor Reflexes  : 
      PLANTAR    : 
CVS: 
RS: 
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LAB: 
      Urine-albumin,sugar,deposit : 
       Blood TC,DC,HB,ESR :   
       BLD sugar,urea creatinine,electrolytes: 
       ECG     : 
       X-RAY Chest PA   : 
       SPO2     : 
       Pseudo cholinesterase level : 
      Total dose of Atropine required for treatment: 
       Outcome    : 
 66 
Sl.No Age 
Sex 
Male/ 
Female 
IP   
No. 
 
TIME 
INTERVAL 
BETWEEN 
EXPOSURE 
TO 
ADMISSION 
IN (HOURS) 
ROUTE OF 
EXPOSURE 
SYMPTOMS 
 
BLOOD 
SUGAR 
IN 
mgm 
/dl 
 
BLOOD 
UREA 
IN 
mgm/dl 
 
SERUM 
CREATINE 
IN  mgm/dl 
 
PSEUDOCHOLINE 
ESTERASE LEVEL 
U/L 
 
RESPIRATORY 
FAILURE 
 
TOTAL 
AMOUNT 
OF 
ATROPINE 
IN mgm/dl 
 
OUTCOME 
 
1 24 M 48149 8 O M 138 26 1.2 863 N 252 R 
2 35 M 48378 6 O M 108 20 1 2980 N 180 R 
3 39 M 48452 4 O M+N 60 26 0.9 691 Y 144 E 
4 18 F 48502 5 O M+N 140 30 1.1 2172 Y 192 E 
5 28 M 48516 4 I M 107 24 0.9 2843 N 204 R 
6 20 M 48588 5 O M 124 22 1 3479 N 264 R 
7 29 F 48753 2 O M+N 112 20 1 2988 N 288 R 
8 58 F 48788 3 O M 186 26 1.2 2649 N 156 R 
9 22 M 48885 2 O M 104 22 0.9 1061 N 132 R 
10 32 F 48995 8 O M+N 94 26 1 1760 Y 240 E 
11 19 M 48992 4 O M 108 24 1 1743 Y 348 R 
12 21 F 48169 2 O M+N 96 30 1.2 2824 Y 180 R 
13 42 M 49241 6 O M 120 20 1 4486 N 120 R 
14 24 M 49364 4 O M 126 22 0.9 2678 N 132 R 
15 31 F 49601 2 O M 124 20 1 973 N 216 R 
16 30 M 49760 4 O M 112 26 1 3210 N 180 R 
17 18 M 49907 2 O M 92 24 1 1621 N 264 R 
18 43 M 50070 1.5 O M+N 142 28 1 5249 Y 228 E 
19 29 F 50038 9 O M 98 28 1 1084 N 300 R 
20 21 M 50610 5 O M+N 94 20 1.2 3842 Y 264 R 
21 27 F 50872 6 O M 96 28 1 2960 N 144 R 
22 53 M 50908 3 I M+N 102 26 1 3109 Y 360 E 
23 31 F 50990 6 O M 186 24 1 2761 N 180 R 
24 23 M 51085 10 O N+C 120 20 1.2 2188 Y 264 E 
25 33 M 51278 8 I M 114 32 1.1 1242 N 288 R 
26 17 F 51296 10 O M 94 30 0.9 218 N 120 R 
27 38 F 51313 1 O M 108 22 1 5104 N 144 R 
28 28 M 51360 5 O M+N 112 26 1 3690 Y 276 E 
29 19 F 50313 4 O M 107 24 1.2 2872 N 48 R 
30 33 M 51974 5 O M 124 30 1 3084 N 168 R 
31 17 M 52039 6 0 M 102 20 0.9 2622 N 264 R 
32 23 M 52047 10 O M+N 110 22 1.1 1431 Y 108 E 
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33 39 F 52557 4 O M 96 26 1 3180 N 144 R 
34 28 M 52570 5 O M 80 24 1 1731 N 348 R 
35 32 F 52719 2 O M+N+C 110 30 1 1018 Y 240 R 
36 21 F 53061 5 O M 124 20 1 3248 N 144 R 
37 62 M 53578 5 O M 107 22 1.4 2212 N 108 E 
38 19 M 53732 2 O M 190 20 1 1914 N 252 R 
39 31 F 53964 4 O M+N 112 26 0.9 3670 Y 144 E 
40 25 M 54373 5 I M+N 142 24 0.8 2649 Y 348 E 
41 24 M 54450 3 O M 108 28 1.2 2977 N 156 R 
42 34 F 54446 2 I M+N 136 40 1 741 Y 360 R 
43 17 M 55092 4 O M 140 24 1 2627 N 168 R 
44 27 M 406 5 O M 60 72 0.9 6246 N 120 R 
45 18 M 408 4 O M+N 92 32 1.1 2193 Y 216 R 
46 31 F 649 6 O M 172 24 0.9 3064 N 120 R 
47 43 M 682 6 I M 116 26 1.4 1267 Y 348 R 
48 22 M 1363 8 O M+N 124 20 1 4827 N 276 R 
49 30 F 1508 5 O M+N 120 24 1.2 2211 Y 132 R 
50 20 M 1663 6 O M+N+C 136 20 1 3182 Y 240 E 
51 48 M 1791 4 I M 112 18 0.9 2173 N 108 R 
52 27 M 1823 4 O M+N 108 28 0.8 5104 Y 168 R 
53 24 F 1895 6 O M+N 126 30 1 3876 N 264 R 
54 25 M 2093 10 O M 132 20 1.1 2198 Y 360 R 
55 41 F 2137 2 O M+N 106 26 1.2 2964 Y 216 E 
56 18 F 2201 6 O M 128 24 1 5082 N 144 R 
57 32 M 2254 6 O M 132 22 1.2 2742 N 300 R 
58 23 M 2465 12 O M+N 90 30 1.2 1434 Y 288 R 
59 22 F 2469 3 O M 96 34 0.9 1765 N 168 R 
60 51 M 2577 4 I M+N 162 26 0.8 2069 Y 264 R 
61 28 M 2633 6 O M+N 168 42 0.8 3108 Y 132 R 
62 39 M 3273 6 O M 286 24 0.9 2976 N 264 R 
63 40 M 3291 4 I M+N 110 30 0.8 2174 Y 132 E 
64 27 M 3296 5 O M 123 25 1 1176 Y 288 R 
65 34 F 3727 4 O M+N 134 22 1 3124 N 48 R 
66 64 M 4206 6 O M+N 142 20 0.9 2961 Y 324 E 
67 29 F 4218 2 O M 92 24 1.1 3873 N 108 R 
68 24 M 4323 3 O M+N 104 22 0.8 2844 Y 240 E 
69 38 M 4537 4 O M+N 112 30 1 2679 Y 180 R 
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70 31 F 4706 4 O M+N+C 108 26 0.9 2092 Y 276 E 
71 22 M 5335 3 O M 106 24 1.2 1876 N 168 R 
72 23 M 5889 4 O M 124 25 1 2174 N 180 R 
73 33 M 5631 2 I M+N 174 24 0.9 3968 N 60 R 
74 21 M 5996 5 O M 98 20 0.9 847 N 264 R 
75 47 F 6340 4 O M 160 22 1 2940 N 192 R 
76 16 M 6888 4 O M+N 110 32 1 5184 Y 168 R 
77 41 M 7051 3 O M+N 94 20 1 2646 Y 288 E 
78 25 F 7152 6 O M+N 114 24 1.1 2772 N 112 R 
79 43 F 7388 4 O M+N+C 120 22 1 2862 Y 180 E 
80 34 M 7921 3 O M 126 20 0.9 1203 N 96 R 
81 18 M 8344 6 O M 102 24 0.7 3563 N 132 R 
82 28 M 8734 10 O M 96 22 1.1 2364 N 216 R 
83 19 F 9096 4 O M+N 112 24 1.4 1081 Y 168 E 
84 55 M 10592 3 O M+N+C 176 20 1.3 2918 Y 168 R 
85 32 M 11187 3 I M+N+C 124 24 1 2471 Y 216 E 
86 37 F 11190 6 O M 94 22 1 3949 N 132 R 
87 24 M 13150 8 O M+N 152 20 0.8 2621 Y 216 R 
88 29 F 13250 5 O M+N 92 26 0.9 2084 Y 192 R 
89 25 M 13678 4 O M 132 22 0.8 3764 N 96 R 
90 23 M 13885 4 O M 126 26 1.1 6056 N 24 R 
91 52 M 13990 6 O M+N 194 24 1.2 2768 Y 132 R 
92 34 F 14911 3 O M 98 30 0.8 5805 N 180 R 
93 42 M 15886 2 I M 164 20 0.8 3186 N 228 R 
94 25 M 16842 5 O M+N 110 22 1.1 2681 N 108 R 
95 32 M 17324 4 O M+N 94 26 0.9 3212 Y 144 R 
96 29 M 17315 6 O M 114 24 1 2976 N 156 R 
97 39 F 18225 6 O N+C 120 28 1 2049 Y 168 E 
98 34 M 18335 9 O M+N 186 28 1.2 1672 Y 228 R 
99 59 F 19028 3 O M+N 102 20 1 2848 Y 348 E 
100 21 M 19112 4 O M+N 96 28 0.9 2216 Y 336 E 
 
O – Oral  I – Inhalation  Y-Yes  N – No R – Recovered E – Exposure 
M - Muscarinic  N - Nicotinic   C- Central nervous system features 
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ABBREVIATIONS USED IN THIS BOOK 
 
1. OP – Organophosphate 
2. AChE – Acetyl Cholinesterase 
3. PChE – Pseudo Cholinesterase 
4. PAM – Pralidoxime 
5. U/L – Units / Litre 
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